Inhibiting DNA-PK_CS radiosensitizes human osteosarcoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Osteosarcoma survival rates have stagnated, and current treatments cause significant side effects, necessitating novel therapeutic strategies.
• Radiotherapy is generally ineffective against osteosarcoma, suggesting a need for radiosensitizing agents.
• Inhibiting DNA repair mechanisms, specifically DNA-dependent protein kinase catalytic subunit (DNA-PK_CS), is a potential approach for enhancing radiosensitivity.

Purpose of the Study:

• To investigate the expression of DNA-PK_CS in osteosarcoma.
• To evaluate the efficacy of the DNA-PK_CS inhibitor KU60648 as a radiosensitizing agent for osteosarcoma cells in vitro.
• To assess the impact of KU60648 on cell cycle distribution and DNA damage in osteosarcoma cells.

Main Methods:

• Analysis of DNA-PK_CS expression in osteosarcoma tissue specimens and cell lines.
• In vitro treatment of osteosarcoma cell lines (143B and U2OS) with KU60648 and radiation.
• Assessment of cell viability, cell cycle distribution (G2/M phase), and DNA damage marker (γH2AX foci) following treatment.

Main Results:

• DNA-PK_CS was consistently expressed in osteosarcoma tissues and cell lines.
• KU60648 significantly sensitized 143B cells (1.5-fold) and U2OS cells (2.5-fold) to radiation.
• Co-treatment with KU60648 led to increased G2/M phase cell accumulation (55% and 45%) and enhanced DNA damage (59% and 107% increase in γH2AX foci).

Conclusions:

• The small molecule DNA-PK_CS inhibitor KU60648 demonstrates potential as a radiosensitizing agent for osteosarcoma.
• Targeting DNA repair pathways via DNA-PK_CS inhibition offers a promising strategy to improve osteosarcoma treatment outcomes.
• Further investigation into KU60648 as a radiosensitizer for osteosarcoma is warranted.